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(C) of :0:207 mg/dl after diet. Treatment with up to 40 mg simvastatin (S) or
placebo (P) o.d. included diet and - as a reserve medication: - colestyra-
mine, and was pursued for 2.3 years (S/P: 865/835 days). The two treat-
ment groups (see below) were comparable with respect to baseline van~
ables, e,g. average age (49.9/49.1 y), height(175.4/175,2 cm), weight(80.1 /80
kg), blood pressure (123,5/79.8 vs, ·123.1/78.6 mmHg). diastolic hyperten-
sion :0:90 mmHg (9.619.1%), fasting serum glucose :0:120 mg/dl (2.9/5.1%),
family history (47.1/48.0%), smoking (83.6/85.9), ventricular score (1.0/0.9).
coronary score (2.12/1.93 - vessel-disease), and lipid values, with a base-
line LDL-C of 163.8/166.7 mg/dl. Treatment resulted in significant changes of
serum lipids with a decrease of LDL-C by 33% and -1.5% in the Sand P
group, respectively. 204 (81%; 104/1001 patients had a second angiography.
Two primary end points were chosen: - the within-patient change in min-
imum diameter avenged over all assessable coronary segments (""'minD",
determined by quantitative analysis using the CAAS system), and - the vi-
sual Global Change Score ("GCS", Blankenhorn), and calculated according to
Bonferroni-Holme on a multiple significance level of 5%. The detailed results
will be presented.
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1769-41 Lowering of Cholesterol With Simvastatln may
Prevent Development of Heart Failure In Patients
With Coronary Heart Disease
John Kjekshus, Terje Pedersen on behalf of the 4S Study Group. University of Oslo,
Oslo. Norway
While treatment of myocardial overload effectively reduces death from pro-
gression of heart failure, it is not known whether the retardation of progres-
sive coronary heart disease obtained with lipid lowering treatment will pre-
vent onset of heart failure. In the 4S trial 4444 patients without evidence
of heart failure were randomised to placebo (P), (n = 2221) or simvastatin
20--40 mg (S), (n = 2223) and followed for more than 5 years. In P 189 pa-
tients (8.5%) were diagnosed with heart failure during follow up vs. 147 in
S (6.2%) P < 0.003. Respectively 37 and 24 had occurrence of acute heart
failure. Heart failure patients were more likely to have higher triglyceride and
lower HDL than patients who did not develop congestive heart failure.
Conclusion: Long term prevention with simvastatin prevents occurrence
of heart failure in a cohort of patients with coronary heart disease, without
previous evidence of heart failure.
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1769-51 Reduction of Silent Myocardial Ischemia by
Pravastatln Additional to the Conventional Treatment
of Patients with Angina Pectoris
Ad J. van Boven, J. Wouter Jukema, Aeilko H. Zwinderman, Kong I. Lie. Albert
\I.G. Bruschke, REGRESS study group Interuniversity Cardiology Institute. Utrecht.
The Netherlands
With conventional treatment. including PTCA and CABG, complete abol-
ishment of Silent Myocardial Ischemia (SMI) is not attained. Cholesterol-
lowering therapy restores endothelial function and possibly lowers SM I me-
diated by disturbed vasomotion. We hypothesized that pravastatin 40 mg (PI
in addition of conventional therapy may reduce SMI and studied its 2 year
treatment effect in 339 patients from the REGRESS study, using 48 hour am-
bulatory ECG's. In this placebo controlled study only patients with angina
pectoris, documented coronary artery disease and a cholesterol between 4
and B mmolll are included. During Holter anti-ischemic medication was con-
tinued.
Results: At baseline (B) 28% of the patients had SMI and at follow up (F)
15%. A pronounced reduction of Pwas observed in the development of new
SMI in the group of patients with beta blockers (N = 141) at both B + F:
compared to placebo 7 patients less had new SMI (p = 0.05, Chi-Square) In
the group of patients (N = 173) taking nitrates 10 patients less had new SMI,
(p = 0.01). Also patients with triple anti-anginal medication IN = 72) at B +
F showed a beneficial effect of P on SMI (5 pts.less, p = 0.05). P reduced
number of ischemic episodes, duration of ischemia and ischemic burden.
Without the adjustment for concomitant medication the effect of P was not
significant.
Conclusion: Pravastatin causes an additional reduction of silent myocardial
ischemia in angina pectoris patients, who develop ischemia despite beta
blockers, nitrates or triple medication. A new anti-ischemic mode of action
of pravastatin in this subset is suggested, possibly by improving endothelial
function.
5:15
Inhibitory Effect of Lovastatin on Human Coronary
Smooth Muscle Cell Proliferation
Vidya S. Banka, Peter S. Fail, Vasundhra Sharma Episcopal Heart Institute, Episcopal
Hospital. Philadelphia, PA
Longterm administration of lipid lowering agents has been shown to cause
regression of coronary atherosclerosis. To evaluate the mechanism of such
regression, we studied the effect of Lovastatin (HMG coenzyme A reductase
inhibitor) on the smooth muscle cells cultured from atherosclerotic plaque
obtained from 5 human coronary arteries undergoing directional coronary
atherectomy for de novo lesions. Arterial smooth muscle cell lines were cre-
ated by 3-5 passages. These cells were then placed at a density of 3000
cells/ml in M-199 medium with 10% fetal bovine serum. They were exposed
to Lovastatin at varying concentrations between 10-9 to 10-4 M. The coro-
nary arterial smooth muscle cells were inhibited in a dose dependent man-
ner. The table below shows the actual cell counts at various concentrations
of Lovastatin in the 5 patients.
Effect of Lovastatin on smooth muscle cell proliferation
PT Control Mitogen 10-9 10-8 10-7 10-6 10-5 10-4 M
J.B. 2575 5216 4325 3875 3320 2975 2575 1901
M.P 2879 4390 4125 3979 3629 3098 2095 1971
I.H. 2389 3613 3368 3153 2841 2221 2006 1696
M.L. 2900 5938 4817 3909 3199 2729 2072 1092
we 2830 3729 3210 2710 2093 1773 1292 934
Mean 2715 4581 3969 3525 3016 2559 2008 1519
Conclusion: HMG Coenzyme A reductase inhibitor Lovastatin has a strong
antiporliferative effect on human coronary smooth muscle cells. These ob-
servations suggest that antiproliferative effect of Lovastatin may be respon-
sible for causing regression of atherosclerotic lesions in addition to its lipid
lowering effects.
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1770-1 I Exogenously Administered Growth Hormone and
IGF-1 Alter Intracellular Calcium Handling and
Enhance Cardiac Performance
Hinrik Stromer, Antonio Cittadini, Pamela S. Douglas. James P. Morgan. Beth Israel
Hospital and Harvard Medical School, Boston, MA
To further elucidate the mechanisms by which growth hormone (GH) and
IGF-l modulate cardiac function, we studied isolated, isovolumic, buffer-
perfused rat hearts after 4 weeks of treatment with high doses of GH, IGF-l
or combination of both (G + I). Flow rate was 10 mllmin/g heart wt.. baseline
perfusate Ca2+ was 1.0 mmoill. Functional parameters including systolic and
diastolic pressure (Psys, Pdias' mmHg), maximal +dP/dt/DevP (sec-1) and
(calculated) peak systolic circumferential wall stress (asys, kdyn/m2) were
measured at 50% of the intracardiac balloon volume at which maximal devel-
oped pressure (DevP) occurred. EC50 (/tmolll) of the force Ca2+ relationship
and maximum Ca2+ activated force lasysmx, kdyn/cm2) were assessed by
stepwise increase of Ca2+ in the perfusate and plotting asys vs. intracellu-
lar peak systolic Ca2+ measured by the aequorin bio-Iuminescence method.
Results at baseline and Ca2+ response were as follows:
Psys asys +dPldt/DevP EC50 usysmx
Control 139 ± 5# 68± 5 15.4±0.1 0.67 ± 001 78± 5
IGF-' 169 ± 6#* 68 ± 2 17.7 ± 0.2#* 0.73 ±0.02* 103 ± 4*
GH 162 ± 5#* 67 ± 3 16.5 ± 0.2* 0.74 ± 0.01* 107 ± 4*
G + I 153 ± 4* 69 ± 3 156 ± 0.3 0.72 ± 0.02' 106 ± 2*
Data are mean ± SEM: *p < 0.05 vs. control. #vs. G + I
Pdias. Casys. Cadias. shape and duration of the Ca2+ transient were not in-
fluenced by the treatments. All treatmenls caused a similar increase of heart
wt. although the heart wt. to body wt. ratio remained unchanged. asys was
unchanged by the treatments despite increasing Psys , suggesting a concen-
lric growth pattern. In addition to the increased Psys enhanced systolic per-
formance was demonstrated by an increased asysmx, although this effect is
not seen on asys at baseline due to an increased EC50 .
These data support the hypothesis, that both IGF-l and GH have a direct
effect on cardiac performance by influencing geometry and maximum Ca2+
activated force capacity.
